# reload+after+2024-01-21 08:43:16.641518
address1§131 Hartwell Avenue
address2§Suite 320
city§Lexington
state§MA
zip§02421
country§United States
phone§781 761 4904
fax§339 674 6495
website§https://www.aldeyra.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Todd C. Brady M.D., Ph.D.', 'age': 51, 'title': 'CEO, President & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 909967, 'exercisedValue': 0, 'unexercisedValue': 3757232}, {'maxAge': 1, 'name': 'Mr. Bruce  Greenberg CPA, M.B.A.', 'age': 55, 'title': 'Senior VP of Finance, Interim CFO & Treasurer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 396540, 'exercisedValue': 0, 'unexercisedValue': 224960}, {'maxAge': 1, 'name': 'Dr. Stephen G. Machatha Ph.D.', 'age': 46, 'title': 'Chief Development Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 579573, 'exercisedValue': 0, 'unexercisedValue': 581519}, {'maxAge': 1, 'name': 'Mr. Kelly  Mizer', 'title': 'Vice President of Commercial Strategy & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'David  Burke', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§6
shareHolderRightsRisk§8
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.468
currency§USD
dateShortInterest§1702598400
forwardEps§-0.44
pegRatio§-0.06
exchange§NCM
quoteType§EQUITY
shortName§Aldeyra Therapeutics, Inc.
longName§Aldeyra Therapeutics, Inc.
firstTradeDateEpochUtc§1399037400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§897be644-930d-375e-9e08-51fe235324f6
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§7.0
targetMeanPrice§9.0
targetMedianPrice§9.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§6.631
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
